DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

A novel treatment, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in individuals with ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

New drug lorundrostat shows promising results in lowering blood pressure for patients with resistant hypertension.

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, ...

Agarwal explains that low levels of a hormone called aldosterone might be behind your constant urge to eat salty food. In her words, “Your cravings are your body’s way of whispering what it needs.

Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Increased aldosterone levels can cause hypertension. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Results ...